A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

被引：2
|
作者：
Topp, Max S. [1 ]
Duell, Johannes [1 ]
Li, Jingjin [2 ]
Jankovic, Vladimir [2 ]
Lowy, Israel [2 ]
Sternberg, David [2 ]
Adriaens, Lieve [2 ]
Peterman, Mary [2 ]
Ambati, Srikanth R. [2 ]
Bannerji, Rajat [3 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126670
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4007
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Bannerji, Rajat
    Allan, John N.
    Arnason, Jon E.
    Brown, Jennifer R.
    Advani, Ranjana H.
    Barnes, Jeffrey A.
    Ansell, Stephen M.
    O'Brien, Susan M.
    Chavez, Julio
    Duell, Johannes
    David, Kevin A.
    Martin, Peter
    Joyce, Robin M.
    Charnas, Robert
    Ambati, Srikanth R.
    Adriaens, Lieve
    Ufkin, Melanie
    Zhu, Min
    Li, Jingjin
    Gasparini, Peter
    Ibrahim, Anfal
    Jankovic, Vladimir
    Fiaschi, Nathalie
    Aina, Olulanu
    Zhang, Wen
    Deering, Raquel P.
    Hamon, Sara
    Thurston, Gavin
    Murphy, Andrew J.
    Weinreich, David M.
    Yancopoulos, George D.
    Lowy, Israel
    Sternberg, David
    Topp, Max S.
    BLOOD, 2019, 134
  • [2] Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes
    Bannerji, Rajat
    Arnason, Jon E.
    Advani, Ranjana
    Brown, Jennifer R.
    Allan, John N.
    Ansell, Stephen M.
    Barnes, Jeffrey
    O'Brien, Susan M.
    Chavez, Julio C.
    Duell, Johannes
    Lowy, Israel
    Charnas, Robert
    Sternberg, David
    Ambati, Srikanth
    Adriaens, Lieve
    Ufkin, Melanie
    Yan, Xiaoyu
    Li, Jingjin
    Navarro, Mark
    Gasparini, Peter
    Jankovic, Vladimir
    Fiaschi, Nathalie
    Zhang, Wen
    Hamon, Sara
    Thurston, Gavin
    Topp, Max S.
    BLOOD, 2018, 132
  • [3] A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    Kim, Tae Min
    Alonso, Arancha
    Prince, Miles
    Taszner, Michal
    Cho, Seok-Goo
    Stevens, Don A.
    Poon, Michelle
    Lim, Francesca
    Le Gouill, Steven
    Carpio, Cecilia
    Keating, Mary-Margaret
    Adriaens, Lieve
    Ufkin, Melanie
    Sabir, Ayesha
    Li, Jingjin
    Jankovic, Vladimir
    Zhu, Min
    Brouwer-Visser, Jurriaan
    Leng, Siyang
    Sirulnik, L. Andres
    Chaudhry, Aafia
    Ambati, Srikanth R.
    Seog, Kim Won
    BLOOD, 2020, 136
  • [4] PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.
    Yang, F.
    Zhu, M.
    Toroghi, M.
    Putluri, D.
    Yan, H.
    Davis, J.
    DiCioccio, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S120 - S120
  • [5] Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy
    Bannerji, Rajat
    Advani, Ranjana H.
    Brown, Jennifer R.
    Arnason, Jon E.
    Barnes, Jeffrey A.
    Allan, John N.
    Ansell, Stephen M.
    O'Brien, Susan M.
    Chavez, Julio C.
    Adriaens, Lieve
    Ufkin, Melanie
    Kostic, Ana
    Paccaly, Anne Josee
    Gao, Bo
    Lowy, Israel
    Sternberg, David
    Topp, Max S.
    BLOOD, 2017, 130
  • [6] Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy
    Bannerji, Rajat
    Brown, Jennifer R.
    Advani, Ranjana H.
    Arnason, Jon
    O'Brien, Susan M.
    Allan, John N.
    Chavez, Julio C.
    Barnes, Jeffrey A.
    Joyce, Robin
    Ansell, Stephen
    Topp, Max S.
    Adriaens, Lieve
    Ufkin, Melanie
    Kostic, Ana
    Paccaly, Anne
    Gao, Bo
    Trail, Pamela A.
    Lowy, Israel
    Brownstein, Carrie
    BLOOD, 2016, 128 (22)
  • [7] Safety and efficacy of a novel anti-CD20/CD19 bispecific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).
    Liang, Aibin
    Zhou, Lili
    Li, Ping
    Yu, Wenjuan
    Yang, Min
    Xu, Yangyang
    Ye, Shiguang
    Zhu, Judy
    Huang, Jiaqi
    Zhang, Yan
    Li, Lanfang
    Zhao, Jing
    Li, Jing
    Zheng, Chengxiao
    Zhu, Kevin
    Lan, Liping
    Zhang, Huilai
    Zhou, Daobin
    Yao, Yihong
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.
    Fanale, Michelle A.
    Hamlin, Paul A.
    Park, Steven I.
    Persky, Daniel Oscar
    Higgins, Jack P.
    Burnett, Christine
    Dabovic, Kristina
    Poma, Eric
    Sarapa, Nenad
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] TRANSLATIONAL FINDINGS FOR REGN1979, A HUMAN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY: FROM PRECLINICAL TO FIRST-IN-HUMAN STUDY IN PATIENTS WITH CD20+B-CELL MALIGNANCIES.
    Zhu, M.
    Smith, E.
    Kirshner, J.
    Toroghi, M.
    Davis, J.
    Di-Cioccio, A.
    Retter, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S103 - S103
  • [10] Phase I study of a novel humanized anti-CD20 antibody, BM-ca, in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab
    Tobinai, Kensei
    Ogura, Michinori
    Maruyama, Dai
    Suzuki, Tatsuya
    Kobayashi, Yukio
    Uchida, Toshiki
    Fukuhara, Suguru
    Oyama, Takashi
    Fukuzaki, Tomoharu
    Komatsu, Yasuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345